F-star Therapeutics, Inc.: F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
F-star Therapeutics, Inc.: F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021, a potentially best-in-class tetravalent bispecific antibody targeting both CD137 and PD-L1 will be presented in a poster at the 2021 American Academy of Cancer Research, taking place virtually from April 10-15 and May 17-21. Poster #1864, entitled 'FS222, a Tetravalent Bispecific Antibody Targeting CD137 and...
Source: finanznachrichten.de